Latest News for: histidine

Edit

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO� (copper histidinate), the First ...

Nasdaq Globe Newswire 13 Jan 2026
Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium ... .
Edit

Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)

PR Newswire 13 Jan 2026
Food and Drug Administration ("FDA") has approved ZYCUBO® (copper histidinate) for the treatment of Menkes disease in pediatric patients ... Copper histidinate has also been granted Orphan Designation by the European Medicines Agency.
Edit

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States (Form 8-K) (Fortress Biotech Inc)

Public Technologies 13 Jan 2026
FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States ... Copper histidinate has also been granted Orphan Designation by the European Medicines Agency.
  • 1

Article Search

tools
×
×
×
×